SG Americas Securities LLC Buys 73,334 Shares of ANI Pharmaceuticals, Inc. $ANIP

Key Points

• SG Americas Securities LLC boosted its stake in ANI Pharmaceuticals by 321% in Q4, purchasing 73,334 shares and now owning 96,181 shares (~0.43% of the company) valued at $7.59 million.
• Insiders have been net sellers recently: CFO Stephen P. Carey sold 7,312 shares and SVP Ori Gutwerg sold 2,060 shares, with insiders offloading 27,860 shares worth $2.11 million in the last 90 days (insiders now own 12.70%).
• Analyst sentiment is mildly positive — MarketBeat shows an average rating of "Moderate Buy" and an average target price of $107.33, based on five Buy and three Hold ratings (Guggenheim raised its target to $124 and Barclays initiated coverage with an Overweight rating).

SG Americas Securities LLC lifted its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 321.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 96,181 shares of the specialty pharmaceutical company's stock after buying an additional 73,334 shares during the period. SG Americas Securities LLC owned about 0.43% of ANI Pharmaceuticals worth $7,593,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Advisors Asset Management Inc. bought a new stake in ANI Pharmaceuticals in the first quarter valued at $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of ANI Pharmaceuticals by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company's stock valued at $736,000 after acquiring an additional 470 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of ANI Pharmaceuticals by 0.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company's stock valued at $3,235,000 after purchasing an additional 423 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at $2,706,000. Finally, Legal & General Group Plc grew its holdings in shares of ANI Pharmaceuticals by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 46,712 shares of the specialty pharmaceutical company's stock worth $3,048,000 after purchasing an additional 351 shares during the last quarter. Institutional investors own 76.05% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ANIP. Wall Street Zen cut shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, March 14th. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Zacks Research lowered shares of ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, January 6th. Guggenheim lifted their target price on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a "buy" rating in a research note on Friday, January 16th. Finally, Barclays began coverage on ANI Pharmaceuticals in a report on Tuesday, December 9th. They issued an "overweight" rating and a $100.00 target price on the stock. Five research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $107.33.

Insider Buying and Selling

In related news, CFO Stephen P. Carey sold 7,312 shares of the firm's stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $75.50, for a total value of $552,056.00. Following the completion of the sale, the chief financial officer owned 185,543 shares of the company's stock, valued at $14,008,496.50. This trade represents a 3.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Ori Gutwerg sold 2,060 shares of the business's stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $76.50, for a total transaction of $157,590.00. Following the completion of the transaction, the senior vice president owned 84,782 shares of the company's stock, valued at $6,485,823. This trade represents a 2.37% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 27,860 shares of company stock valued at $2,114,771. Insiders own 12.70% of the company's stock.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock opened at $73.71 on Tuesday. The stock has a 50-day simple moving average of $77.37 and a 200 day simple moving average of $83.58. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of 21.94 and a beta of 0.52. The company has a quick ratio of 2.19, a current ratio of 2.71 and a debt-to-equity ratio of 1.11. ANI Pharmaceuticals, Inc. has a 12-month low of $56.71 and a 12-month high of $99.50.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.